Download Files:

Ethacizine (hydrochloride)

$140$1,200

Products Details

Product Description

– Ethacizine hydrochloride (Ethacizin; NIK-244) is a longer-lasting Class Ic antiarrhythmic agent than Flecainide[1]. Ethacizine hydrochloride (Ethacizin; NIK-244) inhibits the depolarizing current responsible for the intraatrial and His-Purkinje-ventricular conduction[2].

Web ID

– HY-135121

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– Neuroscience-Neuromodulation

Molecular Formula

– C22H28ClN3O3S

References

– [1]Sugiyama A, et al. Comparison of cardiovascular effects of a novel class Ic antiarrhythmic agent, NIK-244, with those of flecainide in isolated canine heart preparations cross-circulated with a donor dog.Jpn J Pharmacol. 1991 May;56(1):1-12.|[2]Satoh H, et al. An electrophysiological comparison of a novel class Ic antiarrhythmic agent, NIK-244 (ethacizin) and flecainide in canine ventricular muscle.Br J Pharmacol. 1989 Nov;98(3):827-32.Med Chem. 2019 Nov 6:115132.

CAS Number

– 57530-40-2

Molecular Weight

– 449.99

Compound Purity

– 98.48

SMILES

– O=C(OCC)NC(C=C1N2C(CCN(CC)CC)=O)=CC=C1SC3=C2C=CC=C3.[H]Cl

Clinical Information

– No Development Reported

Research Area

– Cardiovascular Disease

Solubility

– DMSO : 100 mg/mL (ultrasonic)

Target

– Sodium Channel

Pathway

– Membrane Transporter/Ion Channel

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.